The G protein-coupled receptor-related gene signatures for predicting prognosis and immunotherapy response in bladder urothelial carcinoma

Abstract Bladder urothelial carcinoma (BLCA) is the most common malignant tumor of the urinary tract with a high lethality rate, and its immunotherapy resistance and tumor recurrence have become a major challenge in its clinical treatment. G Protein-Coupled Receptors (GPRs) are the largest family of receptors on the cell membrane surface, involved in multiple signaling pathways, and are excellent targets for oncology drug action. The transcriptome profile, single cell transcriptome profile, and clinical data of BLCA were extracted and integrated from TCGA and GEO databases, respectively. The GPR-related genes were obtained from GSEA-MSigDB database. The GPR-related gene signatures of 15 genes were constructed by using the methods of least absolute shrinkage and selection operator regression, multifactor Cox model. At the same time, tumor microenvironment (TME)-score signatures were constructed based on the immune microenvironment of BLCA, and GPR-TME-score signature was further constructed. The stability of this model was verified by using the external dataset GSE160693. We constructed risk groups by combining BLCA patient prognostic information, and with the help of BLCA scRNA transcriptome profiling, we explored differences in prognosis, immune scores, cell–cell interactions, tumor mutational burden, immune checkpoints, and response to immunotherapy in each risk group. We found that the GPR-TME-score signature was an independent prognostic factor for BLCA patients. the TME-score was a protective factor for the prognosis of BLCA patients. Among BLCA patients, GPR-high + TME-low risk group had the worst prognosis, while GPR-high + TME-high risk group had the best prognosis, and the latter had better immune score and immunotherapy response. The above differences in immune response among the subgroups may be related to the higher immune cell infiltration in the GPR-high + TME-high group. GPR-related gene signatures and TME are closely related to BLCA prognosis and immunotherapy, and GPR-related gene signature can be a useful tool to assess BLCA prognosis and immunotherapy response.

[1]  K. Suda.  Recent Advances in Cancer Immunotherapy , 2021, Biomolecules.

[2]  S. Lee,et al.  The Role of Natural Killer Cells as a Platform for Immunotherapy in Pediatric Cancers , 2019, Current Oncology Reports.

[3]  Yinghao Sun,et al.  Tumor-infiltrating M2 macrophages driven by specific genomic alterations are associated with prognosis in bladder cancer , 2019, Oncology reports.

[4]  H. Wada,et al.  Phenotypic Analysis of Tumor Tissue‐Infiltrating Lymphocytes in Tumor Microenvironment of Bladder Cancer and Upper Urinary Tract Carcinoma , 2019, Clinical genitourinary cancer.

[5]  Jianquan Hou,et al.  Human HLA-F adjacent transcript 10 promotes the formation of cancer initiating cells and cisplatin resistance in bladder cancer , 2018, Molecular medicine reports.

[6]  Rui Qiao,et al.  CXCL5 promotes mitomycin C resistance in non-muscle invasive bladder cancer by activating EMT and NF-κB pathway. , 2018, Biochemical and biophysical research communications.

[7]  D. Enting,et al.  Current management of advanced bladder cancer , 2017 .

[8]  David E. Gloriam,et al.  Trends in GPCR drug discovery: new agents, targets and indications , 2017, Nature Reviews Drug Discovery.

[9]  W. Cao,et al.  miR34a/GOLPH3 Axis abrogates Urothelial Bladder Cancer Chemoresistance via Reduced Cancer Stemness , 2017, Theranostics.

[10]  K. Shimada,et al.  Regulatory T Cells and Tumor-Associated Macrophages in the Tumor Microenvironment in Non-Muscle Invasive Bladder Cancer Treated with Intravesical Bacille Calmette-Guérin: A Long-Term Follow-Up Study of a Japanese Cohort , 2017, International journal of molecular sciences.

[11]  S. Shariat,et al.  Genetic determinants for chemo- and radiotherapy resistance in bladder cancer , 2017, Translational andrology and urology.

[12]  X. Ren,et al.  Positive and negative functions of B lymphocytes in tumors , 2016, Oncotarget.

[13]  J. Lynch,et al.  G Protein-Coupled Receptor Signaling in Stem Cells and Cancer , 2016, International journal of molecular sciences.

[14]  Wei Qin,et al.  Expansion of CRISPR/Cas9 genome targeting sites in zebrafish by Csy4-based RNA processing , 2015, Cell Research.

[15]  Jianfeng Xu,et al.  The Evaluation of the Risk Factors for Non-Muscle Invasive Bladder Cancer (NMIBC) Recurrence after Transurethral Resection (TURBt) in Chinese Population , 2015, PloS one.

[16]  Y. Jiao,et al.  Expression and prognostic value of CD97 and its ligand CD55 in pancreatic cancer , 2014, Oncology letters.

[17]  M. Ebsen,et al.  Tumor‐associated macrophages exhibit pro‐ and anti‐inflammatory properties by which they impact on pancreatic tumorigenesis , 2014, International journal of cancer.

[18]  A. Jemal,et al.  International variations in bladder cancer incidence and mortality. , 2014, European urology.

[19]  Jiajia Zheng,et al.  CXCL5 knockdown expression inhibits human bladder cancer T24 cells proliferation and migration. , 2014, Biochemical and biophysical research communications.

[20]  Yuan-Fei Liu,et al.  GPCR-like signaling mediated by smoothened contributes to acquired chemoresistance through activating Gli , 2014, Molecular Cancer.

[21]  M. Berger,et al.  Overexpression of CD97 Confers an Invasive Phenotype in Glioblastoma Cells and Is Associated with Decreased Survival of Glioblastoma Patients , 2013, PloS one.

[22]  K. Borden,et al.  Mechanisms and insights into drug resistance in cancer , 2013, Front. Pharmacol..

[23]  M. Ebert,et al.  LGR4 and LGR6 are differentially expressed and of putative tumor biological significance in gastric carcinoma , 2012, Virchows Archiv.

[24]  Chao Li,et al.  The Invasion and Metastasis Promotion Role of CD97 Small Isoform in Gastric Carcinoma , 2012, PloS one.

[25]  A. Choudhury,et al.  Metastatic Bladder Cancer: A Review of Current Management , 2011, ISRN urology.

[26]  J. Settleman,et al.  EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer , 2010, Oncogene.

[27]  G. Grabenbauer,et al.  Distribution of immune cells in head and neck cancer: CD8+ T-cells and CD20+ B-cells in metastatic lymph nodes are associated with favourable outcome in patients with oro- and hypopharyngeal carcinoma , 2009, BMC Cancer.

[28]  Yusuke Nakamura,et al.  Inhibition of tumor growth through suppression of angiogenesis by brain-specific angiogenesis inhibitor 1 gene transfer in murine renal cell carcinoma. , 2007, Oncology reports.

[29]  Koichiro Matsumoto,et al.  Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers , 2007, Cancer Immunology, Immunotherapy.

[30]  Markus Loeffler,et al.  Tumorigenesis and Neoplastic Progression Individual Cell-Based Models of Tumor-Environment Interactions Multiple Effects of CD 97 on Tumor Invasion , 2006 .

[31]  L. Coussens,et al.  De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. , 2005, Cancer cell.

[32]  M. Maoz,et al.  G Protein-Coupled Receptors in Cancer , 2016 .